Ophtalmopharma
Sarnen
About Ophtalmopharma
OphthalmoPharma (OPPH) is a pharmaceutical company specializing in the development of ophthalmology treatments. Their product pipeline addresses major unmet medical needs including dry eye syndrome, glaucoma, and age-related macular degeneration (AMD). Ophthalmopharma has granted Altacor exclusive rights for its two proprietary therapeutic products for the treatment of glaucoma and dry eye as well as exclusive rights for its EyeBar, a nutraceutical for the prevention of dry AMD and the preloaded injector for delivery of intraocular lens in cataract and corrective lens replacement surgery (currently known as SOLO).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2007)
- Website: ophthalmopharma.com
- Phone: +41 61 931 46 40
Industries & Categories
Health Care
Canonical: https://fsome.com/organization/ophtalmopharma-3335441 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.